These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21885956)

  • 21. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model.
    Peng HL; Yi YF; Zhou SK; Xie SS; Zhang GS
    Chin Med J (Engl); 2015 Nov; 128(22):3050-4. PubMed ID: 26608985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
    El-Harith el-HA; Kühnau W; Schmidtke J; Gadzicki D; Ahmed M; Krawczak M; Stuhrmann M
    Eur J Med Genet; 2006; 49(4):323-30. PubMed ID: 16829353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary hemorrhagic telangiectasia/avastin.
    Davidson TM; Olitsky SE; Wei JL
    Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation.
    Edwards CP; Shehata N; Faughnan ME
    Ann Hematol; 2012 Dec; 91(12):1959-68. PubMed ID: 23053175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel treatment for patients with hereditary haemorrhagic telangiectasia.
    Farnan TB; Gallagher G; Scally CM
    J Laryngol Otol; 2002 Oct; 116(10):849-50. PubMed ID: 12437844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series.
    Joshi H; Woodworth BA; Carney AS
    J Laryngol Otol; 2011 Nov; 125(11):1176-80. PubMed ID: 21846415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia.
    Hosman A; Westermann CJ; Snijder R; Disch F; Mummery CL; Mager JJ
    Rhinology; 2015 Dec; 53(4):340-4. PubMed ID: 26735132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia.
    Smoot LB; Obler D; McElhinney DB; Boardman K; Wu BL; Lip V; Mullen MP
    Arch Dis Child; 2009 Jul; 94(7):506-11. PubMed ID: 19357124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Early genetic diagnosis in patients with HHT induced severe nosebleed].
    Ji L; Wang Z; Wang Q; Zhang J; Jia J; You S; Bai Y; Zhou X; Zhao S; Zhou Y; Zhang G; Wang H
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Mar; 27(5):241-5. PubMed ID: 23729109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis.
    Harvey RJ; Kanagalingam J; Lund VJ
    Am J Rhinol; 2008; 22(2):182-7. PubMed ID: 18416977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
    Fabi SG; Hill C; Witherspoon JN; Boone SL; West DP
    J Drugs Dermatol; 2009 Aug; 8(8):765-9. PubMed ID: 19663116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia.
    Mahoney EJ; Shapshay SM
    Am J Rhinol; 2006; 20(1):87-90. PubMed ID: 16539301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia.
    Jameson JJ; Cave DR
    Laryngoscope; 2004 Apr; 114(4):705-9. PubMed ID: 15064628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.
    Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C
    Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taking thalidomide out of rehab.
    Akhurst RJ
    Nat Med; 2010 Apr; 16(4):370-2. PubMed ID: 20376039
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
    Wang XY; Chen Y; Du Q
    Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):1114-6. PubMed ID: 23661527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
    Amann A; Steiner N; Gunsilius E
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.